[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502198":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":39,"locations":45,"responsibleParty":80,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":31,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":31,"overallStatus":48,"whyStopped":31,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide","EXPERIMENTAL","Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks.\n\nParticipants will receive 0.50 mg once weekly semaglutide injection for 4 weeks.\n\nParticipants will receive 1.0 mg once weekly semaglutide injection for 6 months.",[13],"Drug: Semaglutide Pen Injector",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Semaglutide Pen Injector","Semaglutide injection",[9],[27],"Ozempic",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Semaglutide placebo injection",[15],null,[33,37],{"name":34,"affiliation":35,"role":36},"Petter M Bjornstad, MD","University of Washington","PRINCIPAL_INVESTIGATOR",{"name":38,"affiliation":5,"role":36},"Kristen Nadeau, MD, MS",[40],{"name":41,"role":42,"phone":43,"phoneExt":31,"email":44},"Kyla Best","CONTACT","720-777-9500","Kyla.Best@cuanschutz.edu",[46,63],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of Colorado Anschutz Medical Campus","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-104.83192,39.72943,{"lat":58,"lon":57},[61,62],{"name":41,"role":42,"phone":43,"phoneExt":31,"email":44},{"name":38,"role":36,"phone":31,"phoneExt":31,"email":31},{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University of Washington Medicine Diabetes Institute (UWMDI)","Seattle","Washington","98109",{"type":55,"coordinates":69},[70,71],-122.33207,47.60621,{"lat":71,"lon":70},[74,78],{"name":75,"role":42,"phone":76,"phoneExt":31,"email":77},"Amanda Bard","504-521-7822","abard@uw.edu",{"name":79,"role":36,"phone":31,"phoneExt":31,"email":31},"Petter Bjornstad, M.D.",{"type":81,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[83],{"name":84,"class":85},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100502198","phase-3-type-1-diabetes-impacts-of-semaglutide-on-cardiovascular-outcomes-100502198",false,"NCT05819138","Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","T1-DISCO","Inclusion Criteria:\n\n* Age 18-49 years\n* 1\\) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis\n* Insulin pump or automated insulin delivery systems\n* Estimated glomerular filtration rate (eGFR) ≥ 45 ml\u002Fmin\u002F1.73m2\n* Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)\n* BMI 20-45 kg\u002Fm2\n* Adequate contraceptive method for females\n\nExclusion Criteria:\n\n* HbA1c \\>9%, recent diabetic ketoacidosis (DKA) or hospitalization\n* Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy\n* History\u002Ffamily history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis\n* Current\u002Fplanned pregnancy or nursing\n* Uncontrolled thyroid disease or hypertension (HTN) (≥ 160\u002F100 mm Hg despite optimal therapy)\n* Use of other non-insulin diabetes medications, insulin sensitizing medications, or systemic steroids in past 3 months\n* Use of atypical antipsychotics\n* Significant systemic illness such as cancer\n* Shellfish\u002Fiodine allergy (only exclusionary to iohexol clearance procedure)\n* MRI or PAH contraindications (only exclusionary to MRI and PAH procedures), GLP-1RA allergy","ALL","18 Years","49 Years",{"count":97,"type":98},60,"ESTIMATED","INTERVENTIONAL",[101],"PHASE3","This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.",[104],"Diabetes Mellitus, Type 1","2026-03-03",{"date":107,"type":108},"2026-03-04","ACTUAL",{"date":110,"type":108},"2023-06-21",{"date":112,"type":98},"2027-12-01",{"name":5,"class":6},2]